Key Takeaways
- Resurrect Bio has closed its Series A funding round at $10.3 million, oversubscribed from the $8.1 million initial close announced in February 2026.
- The round was led by Corteva through its Corteva Catalyst platform, with participation from Calculus Capital, Pymwymic, UKI2S, SynBioVen, and AgFunder.
- Total capital raised since founding now stands at approximately $12.4 million, including the 2023 seed round.
- Funds will be used to scale three core platforms: FloraFold® AI discovery, high-throughput functional biology validation, and the Resurrection platform for reactivating cryptic resistance mechanisms.
- Resurrect Bio is now actively seeking additional joint development agreements with seed companies and breeders to commercialise durable disease-resistance traits.
Resurrect Bio Closes $10.3M Series A to Scale AI-Driven Crop Protection
Resurrect Bio, a UK-based agricultural biotechnology company focused on equipping crops with genetic defences against disease, has completed the final close of its Series A funding round at $10.3 million — oversubscribed from the $8.1 million initial close announced in February 2026. The round was led by Corteva through its Corteva Catalyst platform, with participation from Calculus Capital, Pymwymic, UKI2S (managed by Future Planet Capital), SynBioVen, and AgFunder. Total capital raised since the company's founding now stands at approximately $12.4 million, including its 2023 seed round.
Corteva Partnership Anchors the Round
The oversubscription follows Resurrect Bio's joint development agreement with Corteva, announced in March 2026, to develop disease-resistance traits in corn. The strategic alignment between the two companies positioned Corteva as lead investor, signalling institutional confidence in Resurrect Bio's platform approach to durable crop protection.
“The strength of this raise reflects growing conviction in what we're building: a scalable, AI-driven platform for resurrecting disease resistance in the world's most important crops. It's also a validation of what's possible when you combine the UK's world-class plant science base with commercial ambition to translate it into real-world impact,” said Dr. Cian Duggan, CEO of Resurrect Bio.
Three Platforms at the Core of Resurrect Bio's Strategy
The Series A proceeds will be deployed across Resurrect Bio's three integrated capabilities. The FloraFold® AI in-silico discovery platform predicts interactions between plant and pathogen proteins. A high-throughput functional biology platform then validates those predictions at scale. Finally, the Resurrection platform reactivates cryptic resistance mechanisms already present in elite germplasm — compressing the timeline from discovery to deployment in crop significantly compared to conventional breeding approaches.
Resurrect Bio Eyes New Joint Development Agreements
With the round closed and a growing team in place, Resurrect Bio says it is now actively engaging seed companies and breeders to bring durable disease-resistance traits into commercial pipelines through additional joint development agreements.
“Resurrect Bio's innovative gene-editing platform, which restores native disease-resistance genes in crops, offers a promising solution by reducing dependence on chemicals and boosting yields. The team has built an impressive AI-driven platform that places them at the forefront of a new wave of agricultural innovation,” said Elizabeth Klein-Edmonds, Investment Director at Calculus Capital.
1 Comment